Extensive Stage Small Cell Lung Cancer Treatment Study
The purpose of this study is to assess the safety and efficacy of pembrolizumab plus standard of care (SOC) chemotherapy (etoposide/platinum) in participants with newly diagnosed extensive stage small cell lung cancer who have not previously received systemic therapy for this malignancy.
During each 21-day cycle, participants receive pembrolizumab or placebo infusion plus etoposide infusion on days 1, 2 and 3, plus doctor’s choice of platinum infusion. Participants may receive study treatment for a maximum of up to about 3 years.
In order to participate you must meet the following criteria:
- Have a new diagnosis of small cell lung cancer (SCLC).
- Have stage IV disease.
- Have measurable lesions.
You will be excluded from the study if any of the following criteria apply to you:
- Have received prior systemic therapy for the treatment of SCLC.
- Have known central nervous system metastases and/or carcinomatous meningitis.
This is a partial list of inclusion and exclusion criteria.